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Abstract 
Purpose: To prepare and evaluate some quinoline-pyrazoline-based naphthalenyl thiazole derivatives 
as antimicrobial agents. 
Methods: Some quinoline-pyrazoline-based naphthalenyl thiazoles (5a-5e and 6a-6e) were prepared 
by reacting 5-(2-chloroquinolin-3-yl)-3-substitutedphenyl-4,5-dihydro-1H-pyrazole-1-carbothiamides (4a-
4e) with 2-bromo-1-(1-naphthyl)ethanone and 2-bromo-1-(2-naphthyl)ethanone, respectively. Fourier 
transform infra-red (FTIR), 13C-Nuclear magnetic resonance (13C-NMR), 1H-Nuclear magnetic 
resonance (1H-NMR), elemental analysis, and mass spectrometry were used to elucidate and confirm 
the chemical structures of the target compounds. Serial plate dilution technique was used to evaluate 
the antimicrobial activity of the title compounds using ketoconazole and ofloxacin as standards, and 
their minimum inhibitory concentrations (MIC) were determined. 
Results: A total of ten compounds, (5a-5e) & (6a-6e) were prepared. Compound 6d (R = 4-F, 
naphthalen-2-yl derivative) exhibited antimicrobial activities that were higher than those of the standard 
drug (ofloxacin) against S. aureus (MIC = 25 μg/mL, p < 0.05), S. epidermidis (MIC = 25 μg/mL, p < 
0.0001), K. pneumonia (MIC = 25 μg/mL, p < 0.0001), P. vulgaris (MIC = 25 μg/mL, p < 0.0001) and P. 
citrinum (MIC = 25 μg/mL, p < 0.0001). Compound 5d (R = 4-F, naphthalen-1-yl derivative) displayed 
higher antifungal activity than ketoconazole against C. albicans (MIC = 25 μg/mL, p <0.0001).  
Conclusion: The naphthalen-2-yl derivatives (6a-6e) are superior antimicrobial agents as compared to 
the naphthalen-1-yl derivatives (5a-5e) and the presence of 4-F substituent in 6d and 5d is essential for 
stronger antimicrobial activity. The compound 6d needs further investigations related to its safety and 
efficacy. 
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Antimicrobial resistance (AMR), a current global 
concern for human health, is mostly related to 
the irrational use of antibiotics [1,2]. This has 
caused the emergence of multidrug-resistant 
(MDR) pathogens and has also made treatment 
of many bacterial infections difficult. It is reported 
that the infections caused by the antibiotic 
resistant bacteria kill about twenty thousand 
patients annually in the USA and also leads to 
economic loss [3]. The cases of AMR bacterial 
infections are also increasing in the Kingdom of 
Saudi Arabia due to irrational use of antibiotics 
as well as due to the socio-economic and 
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demographic characteristics of Saudi, non-Saudi 
and pilgrim population [4-7]. Another factor 
contributing to the development of AMR is failure 
to discover new antimicrobial agents [8-10]. 
Accordingly, there is a need to take remedial 
actions with respect to the issues related to the 
antimicrobial resistance.  
 
Thiazolyl heterocycles, quinolinyl heterocycles, 
and pyrazolinyl heterocycles have an important 
place in medicinal chemistry. Recently, review 
articles mentioning the usefulness of thiazolyl 
heterocycles [11,12], quinolinyl heterocycles 
[13,14], and pyrazolinyl heterocycles [15,16] as 
analgesic, anti-inflammatory, antibacterial, 
antifungal, antiviral, antiparasitic, anticoagulant, 
anti-Parkinson’s Disease, anticancer, 
antioxidants, antidiabetic, CNS depressant, and 
antimalarial have been published. Recently, 
thiazolyl pyrazoline derivatives (I) and quinolinyl-
pyrazoline-based thiazole derivatives (II) have 
been postulated as templates for the 
development of new antimicrobial agents [17,18] 
(Figure 1). 
 
On the basis of these findings and our continued 
search for novel heterocyclic antimicrobial agents 
[19-21], some quinoline-pyrazoline-based 
naphthalenyl thiazoles (5a-5e and 6a-6e) were 







Open capillary tube method was used to 
determine the melting points of the synthesized 
compounds which are uncorrected. The FTIR 
spectra in KBr were generated using a 5PC FT-
IR spectrophotometer (Nicolet, Browser Morner, 
USA). The 1H-NMR and 13C-NMR spectra were 
generated using a DRX-300 FT NMR (Germany, 
Bruker) spectrophotometer. Mass spectra were 
generated on a mass spectrometer (70 eV, Jeol-
JMS-D-300, Japan). The C, H and N were 
analysed satisfactorily for the titled compounds 
within the range of ±0.4 % of theoretical value. 
Completion of reaction was monitored by 
checking on pre-coated commercial thin layer 
chromatography plates, by using ultra-violet 
cabinet for visualization purpose. The solvent 
system to run these plates consisted of a mixture 
of toluene, ethyl acetate and formic acid (5:4:1). 
Only analytical grade reagents were used for the 
present work. Ofloxacin was procured from Sun 
Pharmaceuticals, India, as a gift sample. 
Ketoconazole was procured from Cipla, India, as 
a gift sample. Figure 2 provides the route of 




Figure 1: Structures of the postulated antimicrobial lead compounds (I and II), and proposed ones to be 
synthesized (5a-5e and 6a-6e) 
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Figure 2: General procedure for the synthesis of compounds 5a-5e & 6a-6e 
 
The compounds (4a-4e) were prepared 
according to the method provided in the literature 
[18]. The compounds 2-bromo-1-(1-naphthyl) 
ethanone and 2-bromo-1-(2-naphthyl)ethanone 
were prepared according to the method provided 




yl)-4-(naphthalen-1-yl) thiazole (5a-5e) 
 
A mixture of the appropriate compound (4a-4e) 
(0.01 mole), 2-bromo-1-(1-naphthyl)ethanone 
(0.01 mole) in 30 ml of ethanol (99.9%) was 
reflux for about 4 to 6 h. The mixture was cooled, 
the solid was separated, washed with 10% 






A mixture of the appropriate compound (4a-4e) 
(0.01 mole), 2-bromo-1-(2-naphthyl)ethanone 
(0.01 mole) in 30 ml of ethanol (99.9 %) was 
reflux for about 4 to 6 h. The mixture was cooled, 
the solid was separated, washed with 10 % 




The compounds (5a-5e) & (6a-6e) were 
screened for their antimicrobial activity using the 
serial plate dilution technique [23-24] against five 
Gram-positive bacteria; five Gram-negative 
bacteria; and five fungi. The procedure provided 
in our earlier reports [19-21] was followed and 
the minimum inhibitory concentrations (MICs) 
values were also determined with respect to 




The data presented in Table 1, Table 2 and 
Table 3 (n = 6) were analyzed using one-way 
analysis of variance along with Dunnett's 
comparison test in comparison to control group 
and standard group using GraphPad Prism 
version 5.00 for Windows (GraphPad Software 
(www.graphpad.com). The results were 
considered significantly different at p < 0.05. 
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              Table 1: Antibacterial activity of compounds 5a-5e and 6a-6e against Gram-positive bacteria 
 
Compound Activity (%) with respect to standard drug (ofloxacin) 
S. aureus E. faecalis S. epidermidis B. subtilis B. cereus 
5a 67.38a 47.22a 63.39a 55.88a 54.79a 
5b 60.05a 61.41a 53.35a 59.22a 63.34a 
5c 73.84a 62.89a 66.98a 74.54a 89.91a 
5d 85.97a 79.18a 94.09a 91.23a 99.10a 
5e 62.38c 47.51a 45.98c 50.21a 57.71a 
6a 72.79a 65.61a 69.65a 57.50a 67.42a 
6b 58.83a 50.50a 60.51a 59.31a 74.22a 
6c 82.73c 82.49a 90.44a 80.57a 89.91a 
6d 100.60c 92.01a 101.37a 91.85a 99.46a 
6e 62.99a 44.50b 39.18a 46.50a 53.86a 
Ofloxacin 100.00%a 100.00%a 100.00a 100.00a 100.00a 
Control 0 0 0 0 0 
a = p <0.0001 with respect to the control and/or the standard; b = p <0.0001 with respect to the control and p 
<0.001 as compared to the standard; c = p <0.0001 with respect to the control and p <0.05 with respect to the 
standard; d = p <0.0001 with respect to the control and p > 0.05 as compared to the standard 
 
Table 2: Antibacterial activity of compounds 5a-5e and 6a-6e against Gram-negative bacteria 
 
Compound Activity (%) with respect to the standard drug (ofloxacin) 
E. coli P. aeruginosa K. pneumonia B. bronchiseptica P. vulgaris 
5a 75.65a 72.27a 87.14a 68.15a 76.24a 
5b 70.59a 69.69a 74.89a 74.17a 79.09a 
5c 92.73a 84.33a 93.29a 86.57a 90.30a 
5d 96.57a 99.75a 99.16a 94.33a 99.69a 
5e 76.44b 72.48a 89.98a 68.53a 70.06a 
6a 68.62a 70.47a 69.58a 79.42a 67.19a 
6b 78.09a 77.76a 72.11a 65.43b 77.34c 
6c 82.95a 87.36b 87.57a 88.34a 90.85a 
6d 98.44a 98.70a 100.30a 97.34a 103.45a 
6e 64.67c 67.98a 81.70a 81.61b 85.70d 
Ofloxacin 100.00a 100.00a 100.00a 100.00a 100.00a 
Control 0 0 0 0 0 
a = p <0.0001 with respect to the control and/or the standard; b = p <0.0001 with respect to the control and p 
<0.001 with respect to the standard; c = p <0.0001 with respect to the control and p <0.05 with respect to the 
standard; d = p <0.0001 with respect to the control and p > 0.05 with respect to the standard 
 
Table 3: Antifungal activity data of compounds 5a-5e and 6a-6e against fungi 
 
Compound Activity (%) with respect to standard drug (ketoconazole) 
C. albicans A. niger A. flavus M. purpureous P. citrinum 
5a 68.21a 85.80a 82.97a 72.80a 79.08a 
5b 79.76a 80.71a 84.22c 77.71a 85.65a 
5c 93.92a 89.49a 91.26c 86.18a 89.05a 
5d 106.16a 96.50a 96.33a 96.07a 96.69a 
5e 82.40a 83.85a 80.88b 78.51a 84.72a 
6a 71.57a 76.25a 65.37d 74.71a 91.09a 
6b 87.48a 93.52b 89.14b 89.71a 93.72a 
6c 91.99a 94.48a 93.96b 92.06a 94.02a 
6d 99.93a 96.50a 96.04a 95.48a 103.80a 
6e 85.46a 86.76a 92.32a 84.75b 87.25a 
Ketoconazole 100.00a 100.00a 100.00a 100.00a 100.00a 
Control 0 0 0 0 0 
a = p <0.0001 with respect to the control and/or the standard; b = p <0.0001 with respect to the control and p 
<0.001 with respect to the standard; c = p <0.0001 with respect to the control and p <0.05 with respect to the 
standard; d = p <0.0001 with respect to the control and p > 0.05 with respect to the standard 
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The synthetic route for the preparation of the 
compounds (5a-5e) & (6a-6e) is depicted in 
Scheme 1. The compounds (4a-4e) were 
synthesized according to the method described 
in the literature [18]. The compounds (5a-5e) 
were prepared by reacting compounds (4a-4e) 
with 2-bromo-1-(1-naphthyl)ethanone using 
ethanol as solvent. Similarly, the compounds (6a-
6e) were prepared by reacting compounds (4a-
4e) with 2-bromo-1-(2-naphthyl)ethanone using 
ethanol as solvent. 
  
These compounds were characterized by their 
different melting points with respect to their 
respective starting materials, different Rf values 
in a particular solvent system, spectral data (IR, 
13C-NMR and 1H-NMR) and elemental analysis. 
The IR spectra of the compounds (5a-5e) & (6a-
6e) showed IR peaks for C=N group ranging 
from 1575 cm-1 to 1580 cm-1; and for C=C group 
ranging from 1535 cm-1 to 1540 cm-1. It also 
displayed characteristic IR peak of C-S group of 
thiazole moiety ranging from 1106 cm-1 to 1112 
cm-1. The 1H-NMR spectra of the compounds 
(5a-5e) & (6a-6e) exhibited characteristic signals 
for the methylene protons (C4-H protons) of 
pyrazoline ring. One proton of the methylene 
group of pyrazoline ring appeared as doublet at 
(δ 3.59-3.65) and another proton also appeared 
as doublet (δ 3.87- 3.91).  
 
The C5-H proton of the pyrazoline ring appeared 
as doublet at δ 5.16 - 5.21. The 1H-NMR spectra 
also showed characteristic signals as multiplets 
at δ 7.10-8.15 for aromatic protons. The 13C-
NMR spectra also supported the assigned 
number of carbon atoms. It showed characteristic 
signal at δ 37.0 – 37.5 due to the methylene 
carbon (C4) of the pyrazoline ring and at δ 53.4 
due to the methine carbon (C5) of the pyrazoline 
ring. The signals at about δ 166.3 – 166.6 arose 
due to the C2 carbon of the thiazole ring. The 
mass spectra and the elemental analysis data for 
the compounds (5a-5e) & (6a-6e) were also in 
accordance with the assigned chemical 
structures.  
 
The spectral data for the compounds (5a-5e) and 




yl) thiazole (5a) 
 
Yield: 55 %; m.p.:  192 oC; Rf value: 0.71; IR 
(KBr): 1575, 1536, 1109; 1H-NMR (DMSO-d6, 
400 MHz) δ ppm: 3.61 (d, J=17Hz, 1H), 3.89 (d, 
J=17Hz, 1H), 5.17 (d, J=18Hz, 1H), 7.15-8.10 
(m, 17H, Ar-H); 13C-NMR (DMSO-d6, 100 MHz) δ 
ppm: 37.0 (C4 of the pyrazoline ring), 53.4 (C5 of 
the pyrazoline ring), 105.0 (C5 of the thiazole 
ring), 121.1, 123.4, 124.3 (2C), 124.6, 125.0, 
125.3, 125.5, 126.3 (3C), 126.8, 127.9, 128.1, 
128.3, 128.6, 128.9, 130.4, 130.7, 132.2 (2C), 
135.2, 138.6, 143.4, 145.8, 149.7 (C3 of the 
pyrazoline ring), 149.9 (C5 carbon of the 
quinoline ring), 166.5 (C2 carbon of the thiazole 
ring); Mass (m/z): 550 (M+, 100%), 551 (M++1), 
276, 184, 138, 111, 92; Elemental Analysis 
(C31H20Cl2N4S): Calcd.: C, 67.51; H, 3.65; N, 






Yield: 60 %; m.p.: 210 oC; Rf value: 0.77; IR 
(KBr): 1578, 1539, 1111; 1H-NMR: 3.60 (d, 
J=17Hz, 1H), 3.90 (d, J=17Hz, 1H), 5.19 (d, 
J=18Hz, 1H), 7.13-8.11 (m, 17H, Ar-H); 13C-
NMR: 37.5 (C4 of the pyrazoline ring), 53.4 (C5 of 
the pyrazoline ring), 105.0 (C5 of the thiazole 
ring), 113.6, 116.2, 121.1, 122.4, 123.4, 124.3 
(2C), 124.6, 125.0, 125.3, 125.5, 126.3 (3C), 
127.9, 128.8 (2C), 130.6, 130.7, 132.2, 134.2, 
138.6, 143.4, 145.8, 149.7 (C3 of the pyrazoline 
ring), 149.9  (C5 carbon of the quinoline ring), 
157.6 (Ar-C), 166.4 (C2 carbon of the thiazole 
ring); Mass (m/z): 534 (M+, 100%), 535 (M++1), 
268, 179, 134, 107, 90; Elemental Analysis 
(C31H20ClFN4S): Calcd.: C, 69.59; H, 3.76; N, 






Yield: 60 %; m.p.: 222 oC; Rf value: 0.71; IR 
(KBr): 1580, 1540, 1106; 1H-NMR: 3.64 (d, 
J=17Hz, 1H), 3.88 (d, J=17Hz, 1H), 5.21 (d, 
J=18Hz, 1H), 7.16-8.13 (m, 17H, Ar-H); 13C-
NMR: 37.4 (C4 of the pyrazoline ring), 53.4 (C5 of 
the pyrazoline ring), 105.0 (C5 of the thiazole 
ring), 113.0, 115.8, 121.1, 121.8, 123.4, 124.3 
(2C), 124.6, 125.0, 125.3, 125.5, 126.3 (3C), 
127.9, 128.4, 128.9, 130.7, 132.2, 133.6, 134.2, 
138.6, 143.4, 145.8, 149.7 (C3 of the pyrazoline 
ring), 149.9 (C5 carbon of the quinoline ring), 
161.0 (Ar-C), 166.5 (C2 carbon of the thiazole 
ring); Mass (m/z): 534 (M+, 100 %), 535 (M++1), 
268, 179, 134, 107, 90; Elemental Analysis 
(C31H20ClFN4S): Calcd.: C, 69.59; H, 3.76; N, 
10.46; Found: C: C, 69.51; H, 3.73; N, 10.43. 
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Yield: 65 %; m.p.: 205 oC; Rf value: 0.74; IR 
(KBr): 1579, 1538, 1109; 1H-NMR: 3.59 (d, 
J=17Hz, 1H), 3.89 (d, J=17Hz, 1H), 5.19 (d, 
J=18Hz, 1H), 7.11-8.11 (m, 17H, Ar-H); 13C-
NMR: 37.5 (C4 of the pyrazoline ring), 53.4 (C5 of 
the pyrazoline ring), 105.2 (C5 of the thiazole 
ring), 113.6 (2C), 121.1, 123.4, 124.3 (3C), 
125.0, 125.3, 125.5, 126.3 (3C), 127.5 (2C), 
127.9, 128.9, 130.0, 130.7, 132.2, 134.2, 138.6, 
143.4, 145.8, 149.7 (C3 of the pyrazoline ring), 
149.9 (C5 carbon of the quinoline ring), 163.2, 
166.3 (C2 carbon of the thiazole ring); Mass 
(m/z): 534 (M+, 100%), 535 (M++1), 268, 179, 
134, 107, 90; Elemental Analysis 
(C31H20ClFN4S): Calcd.: C, 69.59; H, 3.76; N, 






Yield: 50 %; m.p.: 210 oC; Rf value: 0.68; IR 
(KBr): 1579, 1535, 1111; 1H-NMR: 3.60 (d, 
J=17Hz, 1H), 3.87 (d, J=17Hz, 1H), 5.18 (d, J=18 
Hz, 1H), 7.14-8.12 (m, 17H, Ar-H); 13C-NMR: 
37.5 (C4 of the pyrazoline ring), 53.4 (C5 of the 
pyrazoline ring), 105.2  (C5 of the thiazole ring), 
121.1, 123.4, 124.3 (2C), 124.6, 125.0 (3C), 
125.3, 125.5, 125.7 (2C), 126.3 (3C), 127.9, 
128.9, 130.7, 132.2, 134.2, 138.6, 140.5, 143.4, 
145.8, 148.2, 149.7 (C3 of the pyrazoline ring), 
149.9 (C5 carbon of the quinoline ring), 166.5 (C2 
carbon of the thiazole ring); mass (m/z): 561 (M+, 
100%), 562 (M++1), 281, 188, 141, 113, 94; 
Elemental Analysis (C31H20ClN5O2S): Calcd.: C, 
66.24; H, 3.58; N, 12.45; Found: C, 66.23; H, 






Yield: 55 %; m.p.: 189 oC; Rf value: 0.73; IR 
(KBr): 1580, 1538, 1112; 1H-NMR: 3.63 (d, 
J=17Hz, 1H), 3.90 (d, J=17Hz, 1H), 5.16 (d, 
J=18Hz, 1H), 7.10-8.12 (m, 17H, Ar-H); 13C-
NMR: 37.0 (C4 of the pyrazoline ring), 53.4 (C5 of 
the pyrazoline ring), 105.1 (C5 of the thiazole 
ring), 124.2 (3C), 124.6, 125.0, 125.3 (3C), 
125.5, 125.6, 126.1 (2C), 126.8, 127.9, 128.1, 
128.3, 128.6, 128.9, 130.4 (2C), 131.8, 134.2, 
135.2, 143.4, 148.2, 149.7 (C3 of the pyrazoline 
ring), 149.9 (C5 carbon of the quinoline ring), 
166.4 (C2 carbon of the thiazole ring); mass 
(m/z): 550 (M+, 100%), 551 (M++1), 276, 184, 
138, 111, 92; Elemental Analysis (C31H20Cl2N4S): 
Calcd.: C, 67.51; H, 3.65; N, 10.15; Found: C, 






Yield: 60 %; m.p.: 214 oC; Rf value: 0.63; IR 
(KBr): 1576, 1537, 1110; 1H-NMR: 3.62 (d, 
J=17Hz, 1H), 3.88 (d, J=17Hz, 1H), 5.19 (d, 
J=18Hz, 1H), 7.14-8.13 (m, 17H, Ar-H); 13C-
NMR: 37.5 (C4 of the pyrazoline ring), 53.4 (C5 of 
the pyrazoline ring), 105.1 (C5 of the thiazole 
ring), 113.3, 116.2, 122.4, 124.2 (3C), 124.6, 
125.0, 125.3 (3C), 125.5 (2C), 126.1 (2C), 127.9, 
128.8 (2C), 130.5 (2C), 131.8, 134.2, 143.4, 
148.2, 149.7 (C3 of the pyrazoline ring), 149.9 
(C5 carbon of the quinoline ring), 157.6, 166.6 
(C2 carbon of the thiazole ring); Mass (m/z): 534 
(M+, 100%), 535 (M++1), 268, 179, 134, 107, 90; 
Elemental Analysis (C31H20ClFN4S): Calcd.: C, 
69.58; H, 3.76; N, 10.46; Found: C: C, 69.55; H, 






Yield: 50 %; m.p.: 178 oC; Rf value: 0.72; IR 
(KBr): 1580, 1540, 1108; 1H-NMR: 3.65 (d, 
J=17Hz, 1H), 3.91 (d, J=17Hz, 1H), 5.20 (d, 
J=18Hz, 1H), 7.10-8.15 (m, 17H, Ar-H); 13C-
NMR: 37.5 (C4 of the pyrazoline ring), 53.4 (C5 of 
the pyrazoline ring), 105.1 (C5 of the thiazole 
ring), 113.0, 115.8, 121.8, 124.2 (3C), 124.6, 
125.0, 125.3 (3C), 125.5, 125.6, 126.1 (2C), 
127.9, 128.4, 128.9, 130.5, 131.8, 133.6, 134.2, 
143.4, 148.2, 149.7 (C3 of the pyrazoline ring), 
149.9 (C5 carbon of the quinoline ring), 161.0, 
166.4 (C2 carbon of the thiazole ring); Mass 
(m/z): 534 (M+, 100%), 535 (M++1), 268, 179, 
134, 107, 90; Elemental Analysis 
(C31H20ClFN4S): Calcd.: C, 69.58; H, 3.76; N, 






Yield: 65 %; m.p.: 188 oC; Rf value: 0.70; IR 
(KBr): 1577, 1538, 1108; 1H-NMR: 3.62 (d, 
J=17Hz, 1H), 3.89 (d, J=17Hz, 1H), 5.18 (d, 
J=18Hz, 1H), 7.11-8.13 (m, 17H, Ar-H); 13C-
NMR: 37.5 (C4 of the pyrazoline ring), 53.4 (C5 of 
the pyrazoline ring), 105.2 (C5 of the thiazole 
ring), 114.6 (2C), 124.2 (3C), 124.6, 125.0, 125.3 
(3C), 125.5 (2C), 126.1 (2C), 127.5 (2C), 127.9, 
128.9, 130.0, 130.5, 131.8, 134.2, 143.4, 148.2, 
149.7 (C3 of the pyrazoline ring), 149.9 (C5 
carbon of the quinoline ring), 163.2, 166.5 (C2 
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carbon of the thiazole ring); Mass (m/z): 534 (M+, 
100%), 535 (M++1), 268, 179, 134, 107, 90; 
Elemental Analysis (C31H20ClFN4S): Calcd.: C, 
69.58; H, 3.76; N, 10.46; Found: C: C, 69.57; H, 






Yield: 55 %; m.p.: 196 oC; Rf value: 0.69; IR 
(KBr): 1578, 1538, 1109; 1H-NMR: 3.61 (d, 
J=17Hz, 1H), 3.9 1(d, J=17Hz, 1H), 5.20 (d, 
J=18Hz, 1H), 7.14-8.13 (m, 17H, Ar-H); 13C-
NMR: 37.5 (C4 of the pyrazoline ring), 53.4 (C5 of 
the pyrazoline ring), 105.1 (C5 of the thiazole 
ring), 124.2 (3C), 124.6, 125.0 (3C), 125.3 (3C), 
125.5 (2C), 125.7 (2C), 126.1 (2C), 127.9, 128.9, 
130.5, 131.8, 134.2, 140.5, 143.4, 148.2 (2C), 
149.7 (C3 of the pyrazoline ring), 149.9 (C5 
carbon of the quinoline ring), 165.5 (C2 carbon of 
the thiazole ring); Mass (m/z): 561 (M+, 100 %), 
562 (M++1), 281, 188, 141, 113, 94; Elemental 
Analysis (C31H20ClN5O2S): Calcd.: C, 66.24; H, 





The data of the antimicrobial activity of the 
compounds (5a-5e and 6a-6e) obtained by serial 
plate dilution technique are listed in Table 1, 
Table 2 and Table 3, respectively. 
 
Compound 6d (R = 4-F, naphthalen-2-yl 
derivative) exhibited MIC of 25 µg/mL and the 
highest activity of 100.60, 92.01, 101.37, 91.85, 
and 99.46 % against S. aureus, E.faecalis, S. 
epidermidis, B. subtilis and B. cereus, 
respectively, in regard to the standard drug. 
Additionally, compound 6d exhibited the highest 
activity of 98.44, 100.30, 97.34, and 103.45 % 
against E.coli, K. pneumonia, B. bronchiseptica, 
and P. vulgaris respectively, in comparison to the 
standard drug. Compound 5d (R = 4-F, 
naphthalen-1-yl derivative) exhibited the highest 
activity of 99.75 % with MIC of 25 μg/mL against 
P. aeruginosa with respect to the standard drug. 
The compound 5d (R = 4-F, naphthalen-1-yl 
derivative) displayed MIC value of 25 μg/mL and 
highest antifungal activity of 106.16, 96.50, 
96.33, and 96.07 % against Candida albicans, A. 
niger, A. flavus and M. purpureous, respectively, 
in comparison to standard drug. The compound 
6d (R = 4-F, naphthalen-2-yl derivative) exhibited 
the highest activity of 96.50 and 103.80 % 




The spectral data and elemental analysis of the 
titled compounds (5a-5e and 6a-6e) were in 
accordance with the assigned chemical 
structures. The disappearance of the 
characteristic IR peaks at about 3370 cm-1 to 
about 3442 cm-1 due to the N-H group, and the 
peaks at about 1330 cm-1 to about 1340 cm-1 due 
to the C=S groups present in the compounds 
(4a-4e) [23], supported the formation of the 
compounds (5a-5e and 6a-6e). The 
disappearance of signal of two amino protons of 
the compounds (4a-4e) at δ 8.44 to 8.68 [23] 
also supported the formation of the compounds 
(5a-5e and 6a-6e). 
 
It is also expected that these compounds might 
be exhibiting their antimicrobial effect by the 
same mechanism as has been reported for 
similar type of compounds. It has also been 
observed that the naphthalen-2-yl derivatives 
(6a-6e) produced better antimicrobial activity 
than the naphthalen-1-yl derivatives (5a-5e). The 
compounds (5a-5e and 6a-6e) were also found 
to be better antibacterial agents against Gram 
negative bacteria. This effect may be because of 
the presence of more aromatic groups that 
impart lipophilic character to the compounds. The 
structure activity relationship of the compounds 
(5a-5e and 6a-6e) revealed that the presence of 
4-F substituent in naphthalen-2-yl derivative (6d) 
and in naphthalen-1-yl derivative (5d) is required 
for superior antimicrobial activity against the 
gram positive bacteria, gram negative bacteria as 
well as fungi. The replacement of 4-F substituent 
with 4-NO2 substituent (6e) or with 2-F 
substituent (6b) or with 2-Cl substituent (6a) 





The findings for the synthesized compounds (5a-
5e and 6a-6e) indicate that the naphthalen-2-yl 
derivative (6d) with 4-F substituent in the phenyl 
ring yields more potent antimicrobial activity 
against S. aureus, S. epidermidis, K. pneumonia, 
P. vulgaris and P. citrinum. Compound 6d is a 
potential lead compound for further development, 
and therefore, needs to be tested against other 
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